ArticlemLife2026
Functionally cured chronic hepatitis B: A cure-related occult HBV infection state.
Article in mLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult HBV infection (OBI) is characterized by the presence of replication-competent hepatitis B virus (HBV) DNA (covalently closed circular DNA [cccDNA] and/or relaxed circular DNA [rcDNA]) in the liver and/or HBV DNA in the blood, despite negative hepatitis B surface antigen (HBsAg) serology. The potential risks associated with OBI include HBV blood transmission, diagnostic challenges, and viral reactivation under immunosuppressive therapy. Some patients with OBI may face a higher risk of liver fibrosis compared to those who have achieved complete clearance of the virus. Functional cure is defined as the clearance of HBsAg, with or without hepatitis B surface antibody (anti-HBs) seroconversion, and undetectable serum HBV DNA after finite therapy. It has been recommended as the optimal goal of antiviral treatment for chronic hepatitis B (CHB) by major guidelines. We highlight that patients achieving functional cure represent a distinct form of cure-related OBI, with unique virological features and potential clinical implications. Furthermore, although direct epidemiological evidence remains limited, accumulating studies have demonstrated that OBI cases with undetectable HBV DNA and negative HBsAg serology retain the potential for transfusion transmission. Accordingly, the transfusion-related risk associated with functional cure should not be overlooked. Here, we discuss the definition, virological and immunological basis, prevalence, diagnosis, and clinical significance of OBI, highlighting its link to cccDNA persistence and immune suppression of viral replication. Finally, we emphasize regular follow-up to mitigate the risks of transfusion-related transmission, HBV reactivation, and disease progression. Further research is warranted to elucidate the viral and immune status of functionally cured patients, thereby optimizing treatment strategies and ensuring blood safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.